Possible Anandamide and Palmitoylethanolamide involvement in human stroke
Open Access
- 1 January 2010
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 9 (1) , 47
Abstract
Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to determine eCB peripheral levels in acute stroke patients and evaluate their relationship with clinical disability and stroke volume. A cohort of ten patients with a first acute (within six hours since symptoms onset) ischemic stroke and a group of eight age- and sex-matched normal subjects were included. Groups were also matched for metabolic profile. All subjects underwent a blood sample collection for anandamide (AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) measurement; blood sampling was repeated in patients on admission (T0), at 6 (T1) and 18 hours (T2) thereafter. Patients neurological impairment was assessed using NIHSS and Fugl-Meyer Scale arm subitem (FMSa); stroke volume was determined on 48 h follow-up brain CT scans. Blood samples were analyzed by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. 1)T0 AEA levels were significantly higher in stroke patients compared to controls. 2)A significant inverse correlation between T0 AEA levels and FMSa score was found. Moreover a positive correlation between T0 AEA levels and stroke volume were found in stroke patients. T0 PEA levels in stroke patients were not significantly different from the control group, but showed a significant correlation with the NIHSS scores. T0 2-AG levels were lower in stroke patients compared to controls, but such difference did not reach the significance threshold. This is the first demonstration of elevated peripheral AEA levels in acute stroke patients. In agreement with previous murine studies, we found a significant relationship between AEA or PEA levels and neurological involvement, such that the greater the neurological impairment, the higher were these levels.Keywords
This publication has 36 references indexed in Scilit:
- Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injuryNeuroscience, 2008
- Serum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary ReportPharmacopsychiatry, 2008
- Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatumNature Neuroscience, 2008
- Iron Oxide Particle-Enhanced MRI Suggests Variability of Brain Inflammation at Early Stages After Ischemic StrokeStroke, 2007
- Cannabinoid CB2 Receptor Activation Decreases Cerebral Infarction in a Mouse Focal Ischemia/Reperfusion ModelJournal of Cerebral Blood Flow & Metabolism, 2007
- Oxyhomologation of the Amide Bond Potentiates Neuroprotective Effects of the Endolipid N-PalmitoylethanolamineThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006
- Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemiaNeuroscience, 2004
- Release of Fatty Acid Amides in a Patient With Hemispheric StrokeStroke, 2002
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989